BREVE REVISIÓN SOBRE EL MANEJO FARMACOLÓGICO DE LA DISLIPIDEMIA

Main Article Content

Juan Reynaldo Castellar Buelvas

Abstract

The increase and imbalance of cholesterol and triglyceride in the blood are known as dyslipidemia, which is a pathology that triggers health problems called hypercholesterolemia or hypertriglyceridemia, although hyperchylomicronemia or a decrease in high-density cholesterol could also occur. Dyslipidemia can be accompanied by alterations such as type 2 diabetes mellitus (DM-2), gout, hormonal alterations, alcoholism, chronic renal failure, hypothyroidism, metabolic syndrome and is one of the adverse effects of some drugs such as thiazide diuretics, progestin-only, second-generation progestin, danazol, isotretinoin, acitretin, cyclosporine, azathioprine, sirolimus, amprenavir, indinavir, nelfinavir, ritonavir, saquinavir, clozapine, carbamazepine, phenobarbital, and phenytoin. Currently there are many pharmacological treatments for dyslipidemia, for example, it can be treated with many drugs such as statins, fibrates, bile acid sequestrants, ecetimibe and nicotinic acid. The treatment of dyslipidemia with statins is highlighted because they are very effective, and are capable of reducing LDL, TG, CV mortality, and they raise HDL to a small extent.

Article Details

How to Cite
Castellar Buelvas, J. R. (2022). BREVE REVISIÓN SOBRE EL MANEJO FARMACOLÓGICO DE LA DISLIPIDEMIA. Scientific Journal in Health Sciences, 1(2), 124–132. https://doi.org/10.61324/csalud.2022.vol1i2.23
Section
Artículos Originales

References

REFERENCIAS BIBLIOGRÁFICAS

Triglicéridos: MedlinePlus en español [Internet]. [cited 2021 Apr 17]. Available from: https://medlineplus.gov/spanish/triglycerides.html

Niveles de colesterol: Prueba de laboratorio de MedlinePlus [Internet]. [cited 2021 Apr 17]. Available from: https://medlineplus.gov/spanish/pruebas-de-laboratorio/niveles-de-colesterol/

Fonseca FAH, De Oliveira Izar MC. Dislipidemias. Rev. Bras. Med. 2015;72(7):279–83.

Pollak F, Arteaga A, Serrano V. Dislipidemia y Diabetes Mellitus tipo 2. Revis Asoc Latinoam Diabetes. 2007;17–23.

Fundacion Instituto Catala de Farmacologia. Dislipidemia por farmacos. Butlletí Groc [Internet]. 2001;14, n° 5:5–8. Available from: https://www.icf.uab.cat/assets/pdf/productes/bg/es/bg145.01e.pdf

Repositorio Digital UNESUM: Hiperlipidemia y su Relación con la Esteatosis Hepática No Alcohólica en Personas de la Asociación San Ignacio del Cantón 24 de Mayo. [Internet]. [cited 2021 Apr 17]. Available from: http://repositorio.unesum.edu.ec/handle/53000/1791

Gómez-Puerta JA. Gout: New pathogenic concepts and new therapeutic agents. Rev Colomb Reumatol. 2011;18(3):163–74.

Pascual V, Serrano A, Pedro-Botet J, Ascaso J, Barrios V, Millán J, et al. Enfermedad renal crónica y dislipidemia. Clin Investig Arter [Internet]. 2017 [cited 2021 Apr 17];29(1):22–35. Available from: www.elsevier.es/arteriohttp://dx.doi.org/10.1016/j.arteri.2016.07.0040214-9168/

Tinoco Sánchez DP, Hurtado Montero CA. Relación del hipotiroidismo y dislipidemia en mujeres pos menopáusicas en la Clínica Ginecomast en el año 2013. 2014 [cited 2021 Apr 17]; Available from: http://repositorio.puce.edu.ec:80/xmlui/handle/22000/10804

del Barrera MP, Pinilla AE, Cortés É, Mora G, Rodríguez MN. Síndrome metabólico: una mirada interdisciplinaria Metabolic syndrome: an interdisciplinary outlook. 2008 [cited 2021 Apr 17];15(3). Available from: http://www.idf.org/home/

Abel L, Carlos Aguilar S, Eric Alexanderson R, Miguel Ahumada A, Marco Alcocer G, Arenas JL, et al. Mexican guidelines in the diagnosis and treatment of dyslipidemias and atherosclerosis. Statement of the Mexican Society of Cardiology. Med Interna Mex. 2020;36(3):390–413.

El 70% de la población mundial sufre ateroesclerosis o endurecimiento de las arterias - La Tercera [Internet]. [cited 2021 Apr 17]. Available from: https://www.latercera.com/noticia/el-70-de-la-poblacion-mundial-sufre-ateroesclerosis-o-endurecimiento-de-las-arterias/

Carvajal C, Clave P. Revisión Bibliográfica Lipoproteínas: Metabolismo y Lipoproteínas Aterogénicas. 2014 [cited 2021 Apr 17];31(2). Available from: https://www.scielo.sa.cr/pdf/mlcr/v31n2/art10v31n2.pdf

Dislipidemias [Internet]. [cited 2021 Apr 17]. Available from: https://www.elsevier.es/es-revista-offarm-4-pdf-13079594

Estudio de dislipidemia en pacientes adultos Hospital de Machal [Internet]. [cited 2021 Apr 18]. Available from: https://www.ifcc.org/media/477409/2018_dislipidemias_solorzano.pdf

Estatinas, reductores del colesterol | Texas Heart Institute [Internet]. [cited 2021 Apr 18]. Available from: https://www.texasheart.org/heart-health/heart-information-center/topics/estatinas-reductores-del-colesterol/

Martínez Triguero ML, Veses Martín S, Garzón Pastor S, Mijares AH. Alteraciones del metabolismo de las lipoproteínas [Internet]. 19th Editi. Vol. 11, Medicine (Spain). Elsevier Espa8#24; a, S.L.U.; 2012. 1125–1129 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-545-6/00227-1

Rosuvastatin Uses, Side Effects & Warnings - Drugs.com [Internet]. [cited 2021 Apr 18]. Available from: https://www.drugs.com/mtm/rosuvastatin.html

Rosuvastatin | DrugBank Online [Internet]. [cited 2021 Apr 18]. Available from: https://go.drugbank.com/drugs/DB01098

Rosuvastatin- ClinicalKey [Internet]. [cited 2021 Apr Available from: https://clinicalkey.unicartagenaproxy.elogim.com/#!/content/drug_monograph/6-s2.0-2673

Lewkittayakorn J, Kuechoo K, Sukpondma Y, Rukachaisirikul V, Phongpaichit S, Chotigeat W. Lovastatin production by aspergillus sclerotiorum using agricultural waste. Food Technol Biotechnol. 2020;58(2):230–6.

Mach F, Baigent C, Catapano AL, Koskina KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis [Internet]. 2019;290(August 2019):140–205. Available from: https://doi.org/10.1016/j.atherosclerosis.2019.08.014

Correction (Journal of the American College of Cardiology (2019) 73(24) (3168–3209), (S0735109718390338), (10.1016/j.jacc.2018.11.002)) [Internet]. Vol. 73, Journal of the American College of Cardiology. Elsevier USA; 2019 [cited 2021 Apr 18]. p. 3234–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109719351642

Pharmd GJP, Thanassoulis G, Anderson TJ, Pharmd ARB, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult as: recommendations will not necessarily produce successful outcomes in every case. 2021 Canadian Cardiovascular. Can J Cardiol [Internet]. 2021; Available from: https://doi.org/10.1016/j.cjca.2021.03.016

Palacio-Portilla EJ, Roquer J, Amaro S, Arenillas JF, Ayo-Martín O, Castellanos M, et al. Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology. 2020.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J [Internet]. 2013 Dec 1 [cited 2021 Apr 18];34(45):3478–90. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/eht273

Ross JL. Statins in the Management of Pediatric Dyslipidemia. J Pediatr Nurs [Internet]. 2016;31(6):723–35. Available from: http://dx.doi.org/10.1016/j.pedn.2016.07.004

Safarova MS, Kullo IJ. My Approach to the Patient with Familial Hypercholesterolemia. Mayo Clin Proc [Internet]. 2016;91(6):770–86. Available from: http://dx.doi.org/10.1016/j.mayocp.2016.04.013

Peng Y, Zhang X, Zhang T, Grace PM, Li H, Wang Y, et al. Lovastatin inhibits Toll-like receptor 4 signaling in microglia by targeting its co-receptor myeloid differentiation protein 2 and attenuates neuropathic pain. Brain Behav Immun [Internet]. 2019;82(July 2019):432–44. Available from: https://doi.org/10.1016/j.bbi.2019.09.013

Chung L, Bey AL, Towers AJ, Cao X, Kim IH, Jiang Y hui. Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model. Neurobiol Dis [Internet]. 2018 Feb 1 [cited 2021 Apr 18]; 110:129. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0969996117302425